In a prespecified analysis of the trial used to ascertain the impact of alirocumab on PAD events and the association of these events with Lp(a), investigators reported that alirocumab reduced the risk of PAD events (CLI, limb revascularization or amputation for ischemia) (HR 0.69, p = 0.004). The gene discussed is LPA; the disease is peripheral arterial disease.